The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing.

Cell Proliferation / genetics Epigenesis, Genetic Glycine Hydroxymethyltransferase / genetics Humans Lymphoma / genetics Proto-Oncogene Proteins c-bcl-2 / genetics

Journal

Nature cancer
ISSN: 2662-1347
Titre abrégé: Nat Cancer
Pays: England
ID NLM: 101761119

Informations de publication

Date de publication:
2020
Historique:
entrez: 11 2 2021
pubmed: 12 2 2021
medline: 12 2 2021
Statut: ppublish

Résumé

Cancer cells adapt their metabolic activities to support growth and proliferation. However, increased activity of metabolic enzymes is not usually considered an initiating event in the malignant process. Here, we investigate the possible role of the enzyme serine hydroxymethyltransferase-2 (SHMT2) in lymphoma initiation.

Identifiants

DOI: 10.1038/s43018-020-0080-0 PMID: 33569544 PMC: PMC7872152
pubmed: 33569544
doi: 10.1038/s43018-020-0080-0
pmc: PMC7872152
mid: NIHMS1654928
pii: 10.1038/s43018-020-0080-0
doi:

Substances chimiques

Proto-Oncogene Proteins c-bcl-2 0
Glycine Hydroxymethyltransferase EC 2.1.2.1
SHMT protein, human EC 2.1.2.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Pagination

653-664

Subventions

Organisme : NCI NIH HHS
ID : R01 CA248168
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA217694
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA207217
Pays : United States
Organisme : NIGMS NIH HHS
ID : P41 GM108569
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA183876
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA192937
Pays : United States

Déclaration de conflit d'intérêts

Competing interests A.D. has received personal consultancy fees from Roche, Corvus Pharmaceuticals, Physicians’ Education Resource, Seattle Genetics, Takeda, EUSA Pharma and AbbVie, and research grants from Roche. The other authors declare no competing interests.

Références

Basso, K. & Dalla-Favera, R. Germinal centres and B cell lymphomagenesis. Nat. Rev. Immunol. 15, 172–184 (2015).
pubmed: 25712152 doi: 10.1038/nri3814
Huet, S., Sujobert, P. & Salles, G. From genetics to the clinic: a translational perspective on follicular lymphoma. Nat. Rev. Cancer 18, 224–239 (2018).
pubmed: 29422597 doi: 10.1038/nrc.2017.127
Lenz, G. & Staudt, L. M. Aggressive lymphomas. N. Engl. J. Med. 362, 1417–1429 (2010).
pubmed: 20393178 doi: 10.1056/NEJMra0807082 pmcid: 7316377
Pasqualucci, L. et al. Genetics of follicular lymphoma transformation. Cell Rep. 6, 130–140 (2014).
pubmed: 24388756 pmcid: 4100800 doi: 10.1016/j.celrep.2013.12.027
Haluska, F. G., Finver, S., Tsujimoto, Y. & Croce, C. M. The t(8; 14) chromosomal translocation occurring in B-cell malignancies results from mistakes in V–D–J joining. Nature. 324, 158–161 (1986).
pubmed: 3097550 doi: 10.1038/324158a0
Kridel, R., Sehn, L. H. & Gascoyne, R. D. Pathogenesis of follicular lymphoma. J. Clin. Invest. 122, 3424–3431 (2012).
pubmed: 23023713 pmcid: 3461914 doi: 10.1172/JCI63186
Nunez, G. et al. Growth- and tumor-promoting effects of deregulated BCL2 in human B-lymphoblastoid cells. Proc. Natl Acad. Sci. USA 86, 4589–4593 (1989).
pubmed: 2543982 doi: 10.1073/pnas.86.12.4589
Ortega-Molina, A. et al. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nat. Med. 21, 1199–1208 (2015).
pubmed: 26366710 pmcid: 4676270 doi: 10.1038/nm.3943
Jiang, Y. et al. CREBBP inactivation promotes the development of HDAC3-dependent lymphomas. Cancer Discov. 7, 38–53 (2017).
pubmed: 27733359 doi: 10.1158/2159-8290.CD-16-0975
Zhang, J. et al. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. Nat. Med. 21, 1190–1198 (2015).
pubmed: 26366712 pmcid: 5145002 doi: 10.1038/nm.3940
Zhang, J. et al. The CREBBP acetyltransferase is a haploinsufficient tumor suppressor in B-cell lymphoma. Cancer Discov. 7, 322–337 (2017).
pubmed: 28069569 pmcid: 5386396 doi: 10.1158/2159-8290.CD-16-1417
De, S. et al. Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. PLoS Genet. 9, e1003137 (2013).
pubmed: 23326238 pmcid: 3542081 doi: 10.1371/journal.pgen.1003137
Kretzmer, H. et al. DNA methylome analysis in Burkitt and follicular lymphomas identifies differentially methylated regions linked to somatic mutation and transcriptional control. Nat. Genet. 47, 1316–1325 (2015).
pubmed: 26437030 pmcid: 5444523 doi: 10.1038/ng.3413
Yang, M. & Vousden, K. H. Serine and one-carbon metabolism in cancer. Nat. Rev. Cancer 16, 650–662 (2016).
pubmed: 27634448 doi: 10.1038/nrc.2016.81
Ye, J. et al. Serine catabolism regulates mitochondrial redox control during hypoxia. Cancer Discov. 4, 1406–1417 (2014).
pubmed: 25186948 pmcid: 4258153 doi: 10.1158/2159-8290.CD-14-0250
Kaelin, W. G. Jr. & McKnight, S. L. Influence of metabolism on epigenetics and disease. Cell 153, 56–69 (2013).
pubmed: 23540690 pmcid: 3775362 doi: 10.1016/j.cell.2013.03.004
Maddocks, O. D. K., Labuschagne, C. F., Adams, P. D. & Vousden, K. H. Serine metabolism supports the methionine cycle and DNA/RNA methylation through de novo ATP synthesis in cancer cells. Mol. Cell 61, 210–221 (2016).
pubmed: 26774282 pmcid: 4728077 doi: 10.1016/j.molcel.2015.12.014
Kim, D. et al. SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance. Nature 520, 363–367 (2015).
pubmed: 25855294 pmcid: 4533874 doi: 10.1038/nature14363
Anderson, D. D., Quintero, C. M. & Stover, P. J. Identification of a de novo thymidylate biosynthesis pathway in mammalian mitochondria. Proc. Natl Acad. Sci. USA 108, 15163–15168 (2011).
pubmed: 21876188 doi: 10.1073/pnas.1103623108
Morscher, R. J. et al. Mitochondrial translation requires folate-dependent tRNA methylation. Nature 554, 128–132 (2018).
pubmed: 29364879 pmcid: 6020024 doi: 10.1038/nature25460
Minton, D. R. et al. Serine catabolism by SHMT2 is required for proper mitochondrial translation initiation and maintenance of formylmethionyl-tRNAs. Mol. Cell 69, 610–621.e5 (2018).
pubmed: 29452640 pmcid: 5819360 doi: 10.1016/j.molcel.2018.01.024
Kottakis, F. et al. LKB1 loss links serine metabolism to DNA methylation and tumorigenesis. Nature 539, 390–395 (2016).
pubmed: 27799657 pmcid: 5988435 doi: 10.1038/nature20132
Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899–905 (2010).
pubmed: 20164920 pmcid: 2826709 doi: 10.1038/nature08822
Oricchio, E. et al. Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy. J. Exp. Med. 211, 1379–1391 (2014).
pubmed: 24913233 pmcid: 4076578 doi: 10.1084/jem.20132120
Egle, A., Harris, A. W., Bath, M. L., O’Reilly, L. & Cory, S. VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood 103, 2276–2283 (2004).
pubmed: 14630790 doi: 10.1182/blood-2003-07-2469
Pajic, A. et al. Cell cycle activation by c-myc in a Burkitt lymphoma model cell line. Int. J. Cancer 87, 787–793 (2000).
pubmed: 10956386 doi: 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6
Ducker, G. S. et al. Human SHMT inhibitors reveal defective glycine import as a targetable metabolic vulnerability of diffuse large B-cell lymphoma. Proc. Natl Acad. Sci. USA 114, 11404–11409 (2017).
pubmed: 29073064 doi: 10.1073/pnas.1706617114
Ding, J. et al. The histone H3 methyltransferase G9A epigenetically activates the serine-glycine synthesis pathway to sustain cancer cell survival and proliferation. Cell Metab. 18, 896–907 (2013).
pubmed: 24315373 doi: 10.1016/j.cmet.2013.11.004
Shyh-Chang, N. et al. Influence of threonine metabolism on S-adenosylmethionine and histone methylation. Science 339, 222–226 (2013).
pubmed: 23118012 doi: 10.1126/science.1226603
Stevenson, W. S. et al. DNA methylation of membrane-bound tyrosine phosphatase genes in acute lymphoblastic leukaemia. Leukemia 28, 787–793 (2014).
pubmed: 24045499 doi: 10.1038/leu.2013.270
Shan, Z., Parker, T. & Wiest, J. S. Identifying novel homozygous deletions by microsatellite analysis and characterization of tumor suppressor candidate 1 gene, TUSC1, on chromosome 9p in human lung cancer. Oncogene 23, 6612–6620 (2004).
pubmed: 15208665 pmcid: 3449089 doi: 10.1038/sj.onc.1207857
La Rochelle, J. et al. Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma. Cancer 116, 4696–4702 (2010).
pubmed: 20629029 doi: 10.1002/cncr.25279
Caro, P. et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell 22, 547–560 (2012).
pubmed: 23079663 pmcid: 3479446 doi: 10.1016/j.ccr.2012.08.014
Pavlova, N. N. & Thompson, C. B. The emerging hallmarks of cancer metabolism. Cell Metab. 23, 27–47 (2016).
pubmed: 26771115 pmcid: 4715268 doi: 10.1016/j.cmet.2015.12.006
Cairns, R. A. & Mak, T. W. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov. 3, 730–741 (2013).
pubmed: 23796461 doi: 10.1158/2159-8290.CD-13-0083
Hoadley, K. A. et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 173, 291–304.e6 (2018).
pubmed: 29625048 pmcid: 5957518 doi: 10.1016/j.cell.2018.03.022
Witkiewicz, A. K. et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun. 6, 6744 (2015).
pubmed: 25855536 pmcid: 4403382 doi: 10.1038/ncomms7744
Beltran, H. et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med. 22, 298–305 (2016).
pubmed: 26855148 pmcid: 4777652 doi: 10.1038/nm.4045
Nikiforov, M. A. et al. A functional screen for Myc-responsive genes reveals serine hydroxymethyltransferase, a major source of the one-carbon unit for cell metabolism. Mol. Cell. Biol. 22, 5793–5800 (2002).
pubmed: 12138190 pmcid: 133987 doi: 10.1128/MCB.22.16.5793-5800.2002
Haggerty, T. J., Zeller, K. I., Osthus, R. C., Wonsey, D. R. & Dang, C. V. A strategy for identifying transcription factor binding sites reveals two classes of genomic c-Myc target sites. Proc. Natl Acad. Sci. USA 100, 5313–5318 (2003).
pubmed: 12702757 doi: 10.1073/pnas.0931346100
Wang, S. S. et al. Polymorphisms in DNA repair and one-carbon metabolism genes and overall survival in diffuse large B-cell lymphoma and follicular lymphoma. Leukemia 23, 596–602 (2009).
pubmed: 18830263 doi: 10.1038/leu.2008.240
Possemato, R. et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476, 346–350 (2011).
pubmed: 21760589 pmcid: 3353325 doi: 10.1038/nature10350
Locasale, J. W. et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat. Genet. 43, 869–874 (2011).
pubmed: 21804546 pmcid: 3677549 doi: 10.1038/ng.890
Esteller, M. et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl Cancer Inst. 92, 564–569 (2000).
pubmed: 10749912 doi: 10.1093/jnci/92.7.564
Merlo, A. et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1, 686–692 (1995).
pubmed: 7585152 doi: 10.1038/nm0795-686
Green, M. R. et al. Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. Nat. Commun. 5, 3904 (2014).
pubmed: 24887457 pmcid: 4321731 doi: 10.1038/ncomms4904
Reich, M. et al. GenePattern 2.0. Nat. Genet. 38, 500–501 (2006).
pubmed: 16642009 doi: 10.1038/ng0506-500
Wendel, H.-G. et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428, 332–337 (2004).
pubmed: 15029198 doi: 10.1038/nature02369
Béguelin, W. et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23, 677–692 (2013).
pubmed: 23680150 pmcid: 3681809 doi: 10.1016/j.ccr.2013.04.011
Mavrakis, K. J. et al. Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev. 22, 2178–2188 (2008).
pubmed: 18708578 pmcid: 2518821 doi: 10.1101/gad.1690808
Singh, K. et al. c-MYC regulates mRNA translation efficiency and start-site selection in lymphoma. J. Exp. Med. 216, 1509–1524 (2019).
pubmed: 31142587 pmcid: 6605752 doi: 10.1084/jem.20181726
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
pubmed: 23104886 pmcid: 23104886 doi: 10.1093/bioinformatics/bts635
Engström, P. G. et al. Systematic evaluation of spliced alignment programs for RNA-seq data. Nat. Methods 10, 1185–1191 (2013).
pubmed: 24185836 pmcid: 4018468 doi: 10.1038/nmeth.2722
Garcia, B. A. et al. Chemical derivatization of histones for facilitated analysis by mass spectrometry. Nat. Protoc. 2, 933–938 (2007).
pubmed: 17446892 pmcid: 4627699 doi: 10.1038/nprot.2007.106
MacLean, B. et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26, 966–968 (2010).
pubmed: 20147306 pmcid: 2844992 doi: 10.1093/bioinformatics/btq054
Camarillo, J. M. et al. Coupling fluorescence-activated cell sorting and targeted analysis of histone modification profiles in primary human leukocytes. J. Am. Soc. Mass Spectrom. 30, 2526–2534 (2019).
pubmed: 31286445 doi: 10.1007/s13361-019-02255-x
Akalin, A. et al. methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. Genome Biol. 13, R87 (2012).
pubmed: 23034086 pmcid: 3491415 doi: 10.1186/gb-2012-13-10-r87
Sanghvi, V. R. et al. The oncogenic action of NRF2 depends on de-glycation by fructosamine-3-kinase. Cell 178, 807–819.e21 (2019).
pubmed: 31398338 doi: 10.1016/j.cell.2019.07.031

Auteurs

Sara Parsa (S)

Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

Ana Ortega-Molina (A)

Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
ORCID: 0000-0003-2782-8994

Hsia-Yuan Ying (HY)

Department of Medicine and Weill Cornell Cancer Center, Weill Cornell Medicine, New York, NY, USA.

Man Jiang (M)

Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

Matt Teater (M)

Department of Medicine and Weill Cornell Cancer Center, Weill Cornell Medicine, New York, NY, USA.

Jiahui Wang (J)

The Jackson Laboratory Cancer Center, Farmington, CT, USA.

Chunying Zhao (C)

Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

Ed Reznik (E)

Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
ORCID: 0000-0002-6511-5947

Joyce P Pasion (JP)

Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

David Kuo (D)

Department of Physiology, Biophysics, and Systems Biology, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA.

Prathibha Mohan (P)

Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
ORCID: 0000-0002-8787-9657

Shenqiu Wang (S)

Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

Jeannie M Camarillo (JM)

Department of Chemistry, Molecular Biosciences and the National Resource for Translational and Developmental Proteomics, Northwestern University, Evanston, IL, USA.
ORCID: 0000-0001-9699-0931

Paul M Thomas (PM)

Department of Chemistry, Molecular Biosciences and the National Resource for Translational and Developmental Proteomics, Northwestern University, Evanston, IL, USA.
ORCID: 0000-0003-2887-4765

Neeraj Jain (N)

Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Javier Garcia-Bermudez (J)

Laboratory of Metabolic Regulation and Genetics, Rockefeller University, New York, NY, USA.

Byoung-Kyu Cho (BK)

Department of Chemistry, Molecular Biosciences and the National Resource for Translational and Developmental Proteomics, Northwestern University, Evanston, IL, USA.

Wayne Tam (W)

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.

Neil L Kelleher (NL)

Department of Chemistry, Molecular Biosciences and the National Resource for Translational and Developmental Proteomics, Northwestern University, Evanston, IL, USA.

Nicholas Socci (N)

Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

Ahmet Dogan (A)

Hematopathology Service, Departments of Pathology and Laboratory Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
ORCID: 0000-0001-6576-5256

Elisa De Stanchina (E)

Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

Giovanni Ciriello (G)

Department of Computational Biology, University of Lausanne, Lausanne, Switzerland.
Swiss Institute of Bioinformatics, Lausanne, Switzerland.
ORCID: 0000-0003-2021-8683

Michael R Green (MR)

Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
ORCID: 0000-0001-6309-9472

Sheng Li (S)

The Jackson Laboratory Cancer Center, Farmington, CT, USA.
ORCID: 0000-0002-9543-6274

Kivanc Birsoy (K)

Laboratory of Metabolic Regulation and Genetics, Rockefeller University, New York, NY, USA.

Ari M Melnick (AM)

Department of Medicine and Weill Cornell Cancer Center, Weill Cornell Medicine, New York, NY, USA.

Hans-Guido Wendel (HG)

Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. wendelh@mskcc.org.
ORCID: 0000-0001-7166-4670

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › The serine hydroxymethyltransferase-2 (SHMT2)...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Épigenèse génétique › The serine hydroxymethyltransferase-2 (SHMT2)...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Transferases › One-carbon group transferases › Hydroxymethyl et formyl transferases › Glycine hydroxymethyltransferase › The serine hydroxymethyltransferase-2 (SHMT2)...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The serine hydroxymethyltransferase-2 (SHMT2)...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Lymphomes › The serine hydroxymethyltransferase-2 (SHMT2)...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Protéines proto-oncogènes c-bcl-2 › The serine hydroxymethyltransferase-2 (SHMT2)...